Neuropsychiatric Symptoms and Blood Biomarkers for Detecting Mild Cognitive Impairment DOI
Yi Jin Leow, Zahinoor Ismail, Seyed Ehsan Saffari

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 10, 2024

Abstract Background Integrating behavioural assessments with blood-based biomarkers (BBM) could improve diagnostic accuracy for Mild Cognitive Impairment (MCI) linked to early-stage neurodegenerative disease (NDD). This study investigates the potential of combining neuropsychiatric symptoms (NPS) BBM enhance differentiation between older adults MCI and those Normal Cognition (NC) in a multi-ethnic Southeast Asian cohort. Methods cross-sectional analyzed baseline data from Biomarkers Study, Singapore(BIOCIS). Data 678 participants (mean[SD]age 59.16[11.02]years, 39.50% males) NC were included. Behavioral assessed using Checklist (MBI-C) Depression, Anxiety, Stress Scales (DASS). Blood samples amyloid-beta (Aβ40, Aβ42), phosphorylated Tau (p-tau181), neurofilament light (NfL) glial fibrillary acidic protein (GFAP). Regression models adjusted age, education, gender, cognitive status (CS) APOE-ε4 used. Discriminative power was evaluated area under curve (AUC) assess combined predictive behavioral biological markers CS, i.e., over CN. Results The included MBI-C scores (total, interest, mood, control) levels NfL, GFAP) significantly higher group, compared CN group. Elevated GFAP (OR:3.636, 95% CI:1.959, 6.751, p<0.001) MBI-C-Mood (OR:2.614, CI:1.538, 4.441, increased likelihood MCI. model, integrating NPS markers, showed strong discriminative ability (AUC = 0.786), 64.7% sensitivity 84.9% specificity at threshold 0.616, (AUC: 0.593) or 0.697) alone. Conclusions Relevance use achieved optimal distinguishing NC, associations GFAP, Mood scores, CS. These findings underscore neuroinflammation mood disturbances as critical factors early NDD, supporting importance dual-dimension screening strategies. represents novel effective approach detection due AD other dementias. integrated framework, leveraging both pathophysiological facilitates earlier diagnosis, potentially improving clinical decision-making enabling targeted disease-modifying therapies individuals disorders.

Language: Английский

Mild behavioral impairment domains are longitudinally associated with pTAU and metabolic biomarkers in dementia‐free older adults DOI Creative Commons
Emmanuel Gonzalez‐Bautista,

Marie Momméja,

Adélaïde De Mauléon

et al.

Alzheimer s & Dementia, Journal Year: 2024, Volume and Issue: 20(7), P. 4692 - 4701

Published: June 14, 2024

Abstract BACKGROUND The mechanisms linking mild behavioral impairment (MBI) and Alzheimer's disease (AD) have been insufficiently explored, with conflicting results regarding tau protein few data on other metabolic markers. We aimed to evaluate the longitudinal association of MBI domains a spectrum plasma biomarkers. METHODS Our study is secondary analysis from NOLAN. biomarkers, including pTau181, was tested using adjusted linear mixed‐effects models. RESULTS sample comprised 359 participants (60% female, mean age: 78.3, standard deviation: 0.3 years). After 1 year, domain abnormal perception associated steeper increases in pTau181. Abnormal perception, decreased motivation, impulse dyscontrol were homocysteine or insulin dysregulation. DISCUSSION Apart our suggest that might also represent dysregulation, probably contributing dementia transition among older adults subjective cognitive decline impairment. Highlights Mild psychosis p. pTau could be pharmacological target treat agitation symptoms. linked dysregulation involving homocysteine.

Language: Английский

Citations

5
Mild Behavioral Impairment and cognitive functions: a systematic review and meta-analysis DOI Creative Commons

Barbara Blasutto,

Francesco Fattapposta,

Maria Casagrande

et al.

Ageing Research Reviews, Journal Year: 2025, Volume and Issue: unknown, P. 102668 - 102668

Published: Jan. 1, 2025

Language: Английский

Citations

0
Blood-based biomarkers in mild behavioral impairment: an updated overview DOI Creative Commons
Efthalia Angelopoulou,

Xenia Androni,

Chiara Villa

et al.

Frontiers in Neurology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 6, 2025

Identifying individuals at-risk for dementia is one of the critical objectives current research efforts, highlighting need simple, cost-effective, and minimally invasive biomarkers. Mild behavioral impairment (MBI), characterized by emergence persistent neuropsychiatric manifestations in older adults, has attracted increasing attention as a potential early indicator cognitive decline dementia. A growing number studies have recently begun to explore relationship between MBI several blood-based biomarkers associated with Alzheimer's disease (AD) pathology, neurodegeneration, well systemic metabolic inflammatory dysregulation. In this context, been lower plasma Aβ42/Αβ40 ratio, higher phosphorylated tau at threonine 181 (p-tau181), increased neurofilament light chain (NfL) levels, disturbances markers, including homocysteine, insulin ferritin, suggesting multifaceted neurobiological basis syndrome. These findings offer insights into underlying pathophysiology MBI, connection symptoms progression AD. narrative review, we aim summarize critically discuss emerging literature evidence linking biomarkers, hoping shed more on MBI's pathophysiology, its AD-related neurobiology, practical utility predicting impairment, guiding interventions managing risk

Language: Английский

Citations

0
Mild behavioral impairment and neurodegeneration: time for a biomarker-based assessment DOI Creative Commons
Maria Francesca Beatino, Lorenzo Lattanzi, Camilla Elefante

et al.

Expert Review of Molecular Diagnostics, Journal Year: 2025, Volume and Issue: unknown

Published: March 18, 2025

KEYWORDS: biomarkersbody fluidsMild Behavioral Impairment (MBI)neurodegenerationneuropsychiatric symptoms (NPS)

Language: Английский

Citations

0
Neuropsychiatric Symptoms and Blood Biomarkers for Detecting Mild Cognitive Impairment DOI
Yi Jin Leow, Zahinoor Ismail, Seyed Ehsan Saffari

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 10, 2024

Abstract Background Integrating behavioural assessments with blood-based biomarkers (BBM) could improve diagnostic accuracy for Mild Cognitive Impairment (MCI) linked to early-stage neurodegenerative disease (NDD). This study investigates the potential of combining neuropsychiatric symptoms (NPS) BBM enhance differentiation between older adults MCI and those Normal Cognition (NC) in a multi-ethnic Southeast Asian cohort. Methods cross-sectional analyzed baseline data from Biomarkers Study, Singapore(BIOCIS). Data 678 participants (mean[SD]age 59.16[11.02]years, 39.50% males) NC were included. Behavioral assessed using Checklist (MBI-C) Depression, Anxiety, Stress Scales (DASS). Blood samples amyloid-beta (Aβ40, Aβ42), phosphorylated Tau (p-tau181), neurofilament light (NfL) glial fibrillary acidic protein (GFAP). Regression models adjusted age, education, gender, cognitive status (CS) APOE-ε4 used. Discriminative power was evaluated area under curve (AUC) assess combined predictive behavioral biological markers CS, i.e., over CN. Results The included MBI-C scores (total, interest, mood, control) levels NfL, GFAP) significantly higher group, compared CN group. Elevated GFAP (OR:3.636, 95% CI:1.959, 6.751, p<0.001) MBI-C-Mood (OR:2.614, CI:1.538, 4.441, increased likelihood MCI. model, integrating NPS markers, showed strong discriminative ability (AUC = 0.786), 64.7% sensitivity 84.9% specificity at threshold 0.616, (AUC: 0.593) or 0.697) alone. Conclusions Relevance use achieved optimal distinguishing NC, associations GFAP, Mood scores, CS. These findings underscore neuroinflammation mood disturbances as critical factors early NDD, supporting importance dual-dimension screening strategies. represents novel effective approach detection due AD other dementias. integrated framework, leveraging both pathophysiological facilitates earlier diagnosis, potentially improving clinical decision-making enabling targeted disease-modifying therapies individuals disorders.

Language: Английский

Citations

0